Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

56.73
-1.7300-2.96%
Volume:343.84K
Turnover:19.74M
Market Cap:2.64B
PE:15.53
High:58.89
Open:58.23
Low:56.70
Close:58.46
52wk High:87.32
52wk Low:47.32
Shares:46.47M
Float Shares:46.47M
Volume Ratio:0.40
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.65
EPS(LYR):3.31
ROE:19.30%
ROA:6.45%
PB:2.89
PE(LYR):17.14

Loading ...

Haemonetics Shares up 11.3% Premarket Q2 Revenue Beat

THOMSON REUTERS
·
Nov 06, 2025

Haemonetics Corp reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 06, 2025

Stock Track | Haemonetics Soars 8.75% Pre-Market on Strong Q2 Earnings, Beating Estimates

Stock Track
·
Nov 06, 2025

Earnings Flash (HAE) Haemonetics Posts Fiscal Q2 Adjusted EPS $1.27, vs. FactSet Est of $0.99

MT Newswires Live
·
Nov 06, 2025

Haemonetics Q2 Adj. EPS $1.27 Beats $1.11 Estimate, Sales $327.316M Beat $311.399M Estimate

Benzinga
·
Nov 06, 2025

Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81

Reuters
·
Nov 06, 2025

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Earnings Release Availability

Reuters
·
Nov 06, 2025

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

THOMSON REUTERS
·
Nov 06, 2025

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 03, 2025

KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment?

TIPRANKS
·
Oct 28, 2025

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

GlobeNewswire
·
Oct 23, 2025

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

GlobeNewswire
·
Oct 23, 2025

Haemonetics (HAE): Exploring Valuation Following Recent Share Price Decline

Simply Wall St.
·
Oct 22, 2025

Haemonetics Is Maintained at Outperform by Barrington Research

Dow Jones
·
Oct 22, 2025

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

GlobeNewswire
·
Oct 20, 2025

Strategic Acquisition of Astria Therapeutics by BioCryst Pharmaceuticals Highlights Potential of Navenibart for HAE Prophylaxis

TIPRANKS
·
Oct 15, 2025

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

GlobeNewswire
·
Oct 14, 2025

Haemonetics Corporation to release second quarter fiscal year 2026 results

Reuters
·
Oct 10, 2025

Haemonetics Is Maintained at Buy by Citigroup

Dow Jones
·
Oct 08, 2025

1 Stock Up by 63% This Year That Could Double, According to Wall Street

Motley Fool
·
Oct 07, 2025